Request Demo
Last update 20 Mar 2025
PEG-Thymosin α1
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms |
Target |
Action agonists |
Mechanism thymosin alpha 1 agonists(Thymosin alpha-1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with PEG-Thymosin α1CTR20132851
PEGTα1联合阿德福韦酯治疗HBeAg阳性慢性乙肝的有效性、安全性——多中心、随机、双盲、平行对照III期临床试验
[Translation] Efficacy and safety of PEGTα1 combined with adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B: a multicenter, randomized, double-blind, parallel-controlled phase III clinical trial
NCT02366247
Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase Ⅲ Trial
NCT02366208
Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg) -Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase II Trial
100 Clinical Results associated with PEG-Thymosin α1
Login to view more data
100 Translational Medicine associated with PEG-Thymosin α1
Login to view more data
100 Patents (Medical) associated with PEG-Thymosin α1
Login to view more data
100 Deals associated with PEG-Thymosin α1
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatitis B, Chronic | Phase 3 | China | 01 Aug 2013 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | (jyfhpefvtw) = orhgoboorb lmsllvnzte (opbbgubasl ) View more | Positive | 31 May 2023 | ||
Thymosin α1+CCRT | (jyfhpefvtw) = valrgnmwui lmsllvnzte (opbbgubasl ) View more | ||||||
Not Applicable | 27 | (qksjsdgmfa) = rimbbtjzrf ndnazgqwyu (cnlxdjppdu, 6.6 - 27.2) | Positive | 31 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free